AbbVie ABBV continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

The revenue for Livmoniplimab is expected to reach an annual total of $27 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

The maker of an augmented reality device that helps surgeons navigate spinal surgery says it's brought in a 20-year medical ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

US President Joe Biden will reportedly block Nippon's (5401.T) $14.1 billion bid to by US Steel (X). According to the report from Bloomberg News, Biden will formally block the deal after it is ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...

The pharmaceutical industry is not lobbying senators to stop the confirmation of long-time critic Robert F. Kennedy Jr.